Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Harbor Mid Cap Value Fund's investment thesis on Regeneron Pharma ($REGN) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$REGNNASDAQRegeneron Pharma

NEUTRAL

Harbor Mid Cap Value Fund—REGN

Fund Letter

Q2 2026

Published August 11, 2026

View Fund Profile

$768.58USD

-7.1% vs last month

$803.48Pitched

-4.3% since pitch

Market Cap$78.8B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

Harbor Mid Cap Value Fund returned 13.99% in Q2 2026, outperforming the Russell Midcap Value Index's 13.40% return through strong stock selection despite value stocks lagging growth across all market-cap ranges. The quarter saw...

— Josef Lakonishok, Menno Vermeulen, Puneet Mansharamani, Greg Sleight, Guy Lakonishok, Gal Skarishevsky

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $REGN, and what else Harbor Mid Cap Value Fund is buying.

Other pitches on $REGN

Other investors who've written on Regeneron Pharma

No other institutional pitches found for this ticker yet.

View all $REGN pitches →